Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
Microbot Medical (Nasdaq: MBOT) has strengthened its commercial leadership team with key appointments ahead of the anticipated LIBERTY® Endovascular Robotic System launch. Allison Rosefort joins as Vice President of Marketing, bringing over 15 years of healthcare marketing experience and a track record of driving double-digit revenue growth. She will oversee downstream marketing and brand management strategies.
The company also welcomed Lisa Dobbins as Director of Human Resources and recently added Paul Mullen as Vice President of Sales. These appointments are strategically timed with the expected FDA decision on LIBERTY® in Q2 2025. The company aims to be prepared for immediate commercial launch following potential FDA clearance.
Rosefort previously served as Senior Director at Topcon Healthcare, while Dobbins joins from Integra LifeSciences where she was HR Business Partner for Global Operations and Quality.
Microbot Medical (Nasdaq: MBOT) ha rafforzato il suo team di leadership commerciale con nomine chiave in vista del previsto lancio del LIBERTY® Endovascular Robotic System. Allison Rosefort entra come Vice Presidente Marketing, portando oltre 15 anni di esperienza nel marketing sanitario e un comprovato successo nel generare una crescita dei ricavi a doppia cifra. Sarà responsabile delle strategie di marketing downstream e gestione del brand.
L'azienda ha inoltre accolto Lisa Dobbins come Direttrice delle Risorse Umane e recentemente ha aggiunto Paul Mullen come Vice Presidente Vendite. Queste nomine sono strategicamente allineate con la prevista decisione della FDA sul LIBERTY® nel secondo trimestre 2025. L'azienda punta a essere pronta per un lancio commerciale immediato in caso di approvazione FDA.
Rosefort ha precedentemente ricoperto il ruolo di Senior Director presso Topcon Healthcare, mentre Dobbins arriva da Integra LifeSciences, dove era HR Business Partner per le Operazioni Globali e la Qualità.
Microbot Medical (Nasdaq: MBOT) ha reforzado su equipo de liderazgo comercial con nombramientos clave antes del esperado lanzamiento del LIBERTY® Endovascular Robotic System. Allison Rosefort se une como Vicepresidenta de Marketing, aportando más de 15 años de experiencia en marketing sanitario y un historial de impulsar un crecimiento de ingresos de dos dígitos. Supervisará las estrategias de marketing downstream y gestión de marca.
La compañía también dio la bienvenida a Lisa Dobbins como Directora de Recursos Humanos y recientemente incorporó a Paul Mullen como Vicepresidente de Ventas. Estos nombramientos están estratégicamente alineados con la esperada decisión de la FDA sobre LIBERTY® en el segundo trimestre de 2025. La empresa busca estar preparada para un lanzamiento comercial inmediato tras una posible aprobación de la FDA.
Rosefort anteriormente fue Directora Senior en Topcon Healthcare, mientras que Dobbins proviene de Integra LifeSciences, donde fue Socia de Recursos Humanos para Operaciones Globales y Calidad.
Microbot Medical(나스닥: MBOT)는 예상되는 LIBERTY® 혈관내 로봇 시스템 출시를 앞두고 주요 임원을 영입하며 상업 리더십 팀을 강화했습니다. 앨리슨 로즈포트가 마케팅 부사장으로 합류하여 15년 이상의 헬스케어 마케팅 경험과 두 자릿수 매출 성장 실적을 보유하고 있습니다. 그녀는 하위 마케팅 및 브랜드 관리 전략을 총괄할 예정입니다.
회사는 또한 리사 도빈스를 인사 담당 이사로 영입했으며 최근에는 폴 멀렌을 영업 부사장으로 추가했습니다. 이 임명들은 2025년 2분기 LIBERTY®에 대한 FDA 결정과 전략적으로 맞물려 있습니다. 회사는 FDA 승인 시 즉각적인 상업 출시 준비를 목표로 하고 있습니다.
로즈포트는 이전에 Topcon Healthcare에서 수석 이사로 근무했으며, 도빈스는 Integra LifeSciences에서 글로벌 운영 및 품질 담당 HR 비즈니스 파트너로 일했습니다.
Microbot Medical (Nasdaq : MBOT) a renforcé son équipe de direction commerciale avec des nominations clés avant le lancement attendu du LIBERTY® Endovascular Robotic System. Allison Rosefort rejoint l’entreprise en tant que Vice-Présidente Marketing, apportant plus de 15 ans d’expérience en marketing dans le secteur de la santé et un parcours marqué par une croissance à deux chiffres du chiffre d’affaires. Elle supervisera les stratégies de marketing en aval et la gestion de la marque.
L’entreprise a également accueilli Lisa Dobbins en tant que Directrice des Ressources Humaines et a récemment recruté Paul Mullen comme Vice-Président des Ventes. Ces nominations sont stratégiquement synchronisées avec la décision attendue de la FDA concernant LIBERTY® au deuxième trimestre 2025. L’entreprise vise à être prête pour un lancement commercial immédiat après une éventuelle approbation de la FDA.
Rosefort a précédemment occupé le poste de Directrice Senior chez Topcon Healthcare, tandis que Dobbins arrive d’Integra LifeSciences où elle était HR Business Partner pour les opérations globales et la qualité.
Microbot Medical (Nasdaq: MBOT) hat sein kommerzielles Führungsteam mit wichtigen Ernennungen gestärkt, bevor das erwartete LIBERTY® Endovascular Robotic System auf den Markt kommt. Allison Rosefort tritt als Vice President Marketing bei und bringt über 15 Jahre Erfahrung im Gesundheitsmarketing sowie eine nachweisliche Erfolgsbilanz bei zweistelligem Umsatzwachstum mit. Sie wird die Downstream-Marketing- und Markenmanagementstrategien leiten.
Das Unternehmen begrüßte außerdem Lisa Dobbins als Personalleiterin und hat kürzlich Paul Mullen als Vice President Sales eingestellt. Diese Ernennungen sind strategisch auf die erwartete FDA-Entscheidung zu LIBERTY® im zweiten Quartal 2025 abgestimmt. Das Unternehmen will für einen sofortigen kommerziellen Start nach möglicher FDA-Zulassung bereit sein.
Rosefort war zuvor Senior Director bei Topcon Healthcare, während Dobbins von Integra LifeSciences kommt, wo sie als HR Business Partner für globale Operationen und Qualität tätig war.
- Strategic expansion of commercial leadership team ahead of potential FDA approval
- Appointment of experienced VP of Marketing with track record of driving double-digit revenue growth
- Recent positive data from pivotal study increases market confidence
- Company positioning for immediate launch post-FDA clearance
- Product not yet FDA approved - regulatory uncertainty remains
- Additional expenses from new executive hires may impact financial performance
The addition of a seasoned VP of Marketing compliments the recent hiring of the Company’s VP of Sales to establish its commercialization readiness infrastructure
Positive data from the recently published pivotal study raises confidence that LIBERTY® will be well received in the market
HINGHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the addition of two senior officers that round out the Company’s U.S. commercial leadership team. Combined with the recent addition of Paul Mullen as Vice President of Sales, the Company is preparing for U.S. commercial launch in advance of the expected U.S. Food and Drug Administration’s (FDA) decision in the second quarter of 2025.
Allison Rosefort, a MedTech and healthcare marketing leader with a track record of successfully launching and managing product lifecycles, has joined Microbot Medical® as Vice President of Marketing. In this newly created role, Mrs. Rosefort will report to Harel Gadot, CEO, President and Chairman, and is expected to work on the Company’s downstream marketing and brand management strategies.
Ms. Rosefort is a results-oriented healthcare executive with over 15 years of marketing experience, and a successful track record of driving double-digit revenue growth. Her expertise leading cross-functional teams, developing data-driven strategies, and executing marketing plans is expected to be invaluable as the Company commercializes LIBERTY®. Prior to joining Microbot Medical®, Ms. Rosefort was Senior Director, Product Marketing & Commercialization at Topcon Healthcare, a leading provider of digital healthcare solutions. In this role, she led the development and execution of comprehensive go-to-market strategies, including pricing, positioning, sales enablement, and marketing collateral, ensuring high-impact and seamless product launches. Prior to Topcon Healthcare, Ms. Rosefort held roles of increasing responsibilities at Integra LifeSciences, Byram Healthcare and ConvaTec, a Bristol Myers Squibb company.
In addition, Lisa Dobbins, an experienced and versatile human resources executive with hands-on MedTech experience, has joined Microbot Medical as Director, Human Resources, a newly created role reporting to Naama Moav, Vice President, Human Resources. Lisa will play an instrumental role as the Company continues to establish its commercial infrastructure and expands its U.S. commercial team.
Previously, she was the HR Business Partner, Global Operations and Quality (Boston and Mansfield, MA) for Integra LifeSciences, a global medical technology company. Additionally, Ms. Dobbins has worked for other cutting-edge medical technology companies, utilizing her experience to hire and build high-performing teams that execute long-term growth objectives.
“The additions of Allison and Lisa, along with the recent hiring of Paul, reflect our commitment to having an experienced commercial leadership team,” commented Harel Gadot. “Our goal has always been to be ready to launch LIBERTY immediately following FDA clearance, and I am confident that we have the talent and experience to successfully implement our commercial strategies.”
LIBERTY® is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and the recent announcement of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
When is the FDA expected to make a decision on Microbot Medical's LIBERTY® system (MBOT)?
Who are the new key executives joining Microbot Medical (MBOT) in 2025?
What is Allison Rosefort's experience before joining Microbot Medical (MBOT)?
Is the LIBERTY® Endovascular Robotic System currently available for sale?
